An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy

Free Radical Biology and Medicine

Volumn 99, Issue , 2016, Pages 544-556

  Zhu, Jiayu ^a   Wang, Huihui ^a   Chen, Feng ^a   Fu, Jingqi ^a   Xu, Yuanyuan ^a   Hou, Yongyong ^a   Kou, Henry H ^a   Zhai, Cheng ^a   Nelson, M Bud ^b   Zhang, Qiang ^c   Andersen, Melvin E ^d   Pi, Jingbo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b MedBlue Incubator Inc   (United States)

^c EMORY UNIVERSITY   (United States)

^d HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

ARE; Cancer therapy; Chemoresistance; Inhibitor; Nrf2

Indexed keywords

2 AMINO ISONICOTINAMIDE; 2 FUROIC HYDRAZIDE; 4 (AMINOMETHYL)PIPERIDINE; 4 AMINOBENZOIC HYDRAZIDE; 4 METHOXYCHALCONE; 4 TOLUIC HYDRAZIDE; AMINOPYRAZINE; ANTIOXIDANT RESPONSE ELEMENT EXPRESSION MODULATOR 1; APIGENIN; ASCORBIC ACID; BRUSATOL; CHALCONE DERIVATIVE; CHRYSIN; CRYPTOTANSHINONE; CYCLOHEXANECARBOXAMIDE; ETHIONAMIDE; IM 3829; ISONIAZID; ISONICOTINAMIDE; LUTEOLIN; METFORMIN; OCHRATOXIN; PHENYLACETIC HYDRAZIDE; PHENYLHYDRAZINE; PROTEIN INHIBITOR; PYRAZINAMIDE; RETINOIC ACID; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOGONIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CUL3 PROTEIN, HUMAN; CULLIN; FLAVONOID; KEAP1 PROTEIN, HUMAN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NFE2L2 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT; VITAMIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARE GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL PROTECTION; CHEMOPROPHYLAXIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NRF2 GENE; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; XENOBIOTIC STRESS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANT RESPONSE ELEMENTS; ANTITUBERCULAR AGENTS; CULLIN PROTEINS; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; VITAMINS;

EID: 84988358996     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.09.010     Document Type: Review

References (197)

1. [1] Moi, P., Chan, K., Asunis, I., et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA 91:21 (1994), 9926–9930.
2. [2] Itoh, K., Chiba, T., Takahashi, S., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236:2 (1997), 313–322.
3. [3] Itoh, K., Wakabayashi, N., Katoh, Y., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:1 (1999), 76–86.
4. [4] Motohashi, H., O'Connor, T., Katsuoka, F., et al. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 294:1–2 (2002), 1–12.
5. [5] Maher, J., Yamamoto, M., The rise of antioxidant signaling–the evolution and hormetic actions of Nrf2. Toxicol. Appl. Pharmacol. 244:1 (2010), 4–15.
6. [6] Itoh, K., Ishii, T., Wakabayashi, N., et al. Regulatory mechanisms of cellular response to oxidative stress. Free Radic. Res. 31:4 (1999), 319–324.
7. [7] Mimura, J., Itoh, K., Role of Nrf2 in the pathogenesis of atherosclerosis. Free Radic. Biol. Med. 88:Pt B (2015), 221–232.
8. [8] Tao, S., Park, S.L., de la Vega, M.R., et al. Systemic administration of the apocarotenoid bixin protects skin against solar UV-induced damage through activation of NRF2. Free Radic. Biol. Med. 89 (2015), 690–700.
9. [9] Hayes, J.D., Dinkova-Kostova, A.T., The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39:4 (2014), 199–218.
10. [10] No, J.H., Kim, Y.B., Song, Y.S., Targeting nrf2 signaling to combat chemoresistance. J. Cancer Prev. 19:2 (2014), 111–117.
11. [11] Jeong, W.S., Jun, M., Kong, A.N., Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid. Redox Signal. 8:1–2 (2006), 99–106.
12. [12] Hayden, A., Douglas, J., Sommerlad, M., et al. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol. Oncol. 32:6 (2014), 806–814.
13. [13] Wu, T., Harder, B.G., Wong, P.K., et al. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?. Mol. Carcinog., 2014.
14. [14] Konstantinopoulos, P.A., Spentzos, D., Fountzilas, E., et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 71:15 (2011), 5081–5089.
15. [15] Jiang, T., Chen, N., Zhao, F., et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 70:13 (2010), 5486–5496.
16. [16] Cho, J.M., Manandhar, S., Lee, H.R., et al. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 260:1–2 (2008), 96–108.
17. [17] Kim, W.D., Kim, Y.W., Cho, I.J., et al. E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells. J. Cell Sci. 125:Pt 5 (2012), 1284–1295.
18. [18] Zhang, P., Singh, A., Yegnasubramanian, S., et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 9:2 (2010), 336–346.
19. [19] Sukumari-Ramesh, S., Prasad, N., Alleyne, C.H., et al. Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells. BMC Cancer, 15, 2015, 118.
20. [20] Zhang, D.D., Lo, S.C., Cross, J.V., et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 24:24 (2004), 10941–10953.
21. [21] Kobayashi, A., Kang, M.I., Okawa, H., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24:16 (2004), 7130–7139.
22. [22] Cullinan, S.B., Gordan, J.D., Jin, J., et al. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 24:19 (2004), 8477–8486.
23. [23] Furukawa, M., Xiong, Y., BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 25:1 (2005), 162–171.
24. [24] Canning, P., Sorrell, F.J., Bullock, A.N., Structural basis of Keap1 interactions with Nrf2. Free Radic. Biol. Med. 88:Pt B (2015), 101–107.
25. [25] Zhang, D.D., Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 38:4 (2006), 769–789.
26. [26] Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27:20 (2013), 2179–2191.
27. [27] McMahon, M., Thomas, N., Itoh, K., et al. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a “tethering” mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 281:34 (2006), 24756–24768.
28. [28] Tong, K.I., Katoh, Y., Kusunoki, H., et al. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell. Biol. 26:8 (2006), 2887–2900.
29. [29] Zhang, D.D., Hannink, M., Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 23:22 (2003), 8137–8151.
30. [30] Mitsuishi, Y., Taguchi, K., Kawatani, Y., et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22:1 (2012), 66–79.
31. [31] Motohashi, H., Katsuoka, F., Engel, J.D., et al. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc. Natl. Acad. Sci. USA 101:17 (2004), 6379–6384.
32. [32] Suzuki, T., Motohashi, H., Yamamoto, M., Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 34:6 (2013), 340–346.
33. [33] Sun, Z., Wu, T., Zhao, F., et al. KPNA6 (Importin {alpha}7)-mediated nuclear import of Keap1 represses the Nrf2-dependent antioxidant response. Mol. Cell. Biol. 31:9 (2011), 1800–1811.
34. [34] Sun, Z., Zhang, S., Chan, J.Y., et al. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol. Cell. Biol. 27:18 (2007), 6334–6349.
35. [35] Baird, L., Lleres, D., Swift, S., et al. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc. Natl. Acad. Sci. USA 110:38 (2013), 15259–15264.
36. [36] Harder, B., Jiang, T., Wu, T., et al. Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. Biochem. Soc. Trans. 43:4 (2015), 680–686.
37. [37] Dinkova-Kostova, A.T., Abramov, A.Y., The emerging role of Nrf2 in mitochondrial function. Free Radic. Biol. Med. 88:Pt B (2015), 179–188.
38. [38] Rachakonda, G., Xiong, Y., Sekhar, K.R., et al. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 21:3 (2008), 705–710.
39. [39] Gao, L., Wang, J., Sekhar, K.R., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J. Biol. Chem. 282:4 (2007), 2529–2537.
40. [40] Suzuki, T., Yamamoto, M., Molecular basis of the Keap1-Nrf2 system. Free Radic. Biol. Med. 88:Pt B (2015), 93–100.
41. [41] McMahon, M., Thomas, N., Itoh, K., et al. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J. Biol. Chem. 279:30 (2004), 31556–31567.
42. [42] Rada, P., Rojo, A.I., Chowdhry, S., et al. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell Biol. 31:6 (2011), 1121–1133.
43. [43] Wu, T., Zhao, F., Gao, B., et al. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev. 28:7 (2014), 708–722.
44. [44] Hast, B.E., Goldfarb, D., Mulvaney, K.M., et al. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res. 73:7 (2013), 2199–2210.
45. [45] Lau, A., Zheng, Y., Tao, S., et al. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. Mol. Cell. Biol. 33:12 (2013), 2436–2446.
46. [46] Cho, H.Y., Kwak, M.K., Pi, J., Nrf2 in host defense: over the rainbow. Oxid. Med. Cell. Longev., 2013, 2013, 975839.
47. [47] Cho, H.Y., Kleeberger, S.R., Nrf2 protects against airway disorders. Toxicol. Appl. Pharmacol. 244:1 (2010), 43–56.
48. [48] Enomoto, A., Itoh, K., Nagayoshi, E., et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci.: Off. J. Soc. Toxicol. 59:1 (2001), 169–177.
49. [49] Liu, M., Reddy, N.M., Higbee, E.M., et al. The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney Int. 85:1 (2014), 134–141.
50. [50] Iizuka, T., Ishii, Y., Itoh, K., et al. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells: Devot. Mol. Cell. Mech. 10:12 (2005), 1113–1125.
51. [51] Xue, P., Hou, Y., Chen, Y., et al. ipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 62:3 (2013), 845–854.
52. [52] Becks, L., Prince, M., Burson, H., et al. Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene. BMC Cancer, 10, 2010, 540.
53. [53] de Vries, H.E., Witte, M., Hondius, D., et al. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?. Free Radic. Biol. Med. 45:10 (2008), 1375–1383.
54. [54] Khor, T.O., Huang, M.T., Prawan, A., et al. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev. Res. 1:3 (2008), 187–191.
55. [55] Iida, K., Itoh, K., Kumagai, Y., et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 64:18 (2004), 6424–6431.
56. [56] Suzuki, T., Shibata, T., Takaya, K., et al. Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels. Mol. Cell. Biol. 33:12 (2013), 2402–2412.
57. [57] Yamamoto, T., Yoh, K., Kobayashi, A., et al. Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem. Biophys. Res. Commun. 321:1 (2004), 72–79.
58. [58] Zhao, R., Yang, B., Wang, L., et al. Curcumin protects human keratinocytes against inorganic arsenite-induced acute cytotoxicity through an NRF2-dependent mechanism. Oxid. Med. Cell. Longev., 2013, 2013, 412576.
59. [59] Zhou, R., Lin, J., Wu, D., Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steatosis. Biochim. Biophys. Acta 1840:1 (2014), 209–218.
60. [60] Duan, X., Liu, D., Xing, X., et al. Tert-butylhydroquinone as a phenolic activator of Nrf2 antagonizes arsenic-induced oxidative cytotoxicity but promotes arsenic methylation and detoxication in human hepatocyte cell line. Biol. Trace Elem. Res. 160:2 (2014), 294–302.
61. [61] Duan, X., Li, J., Li, W., et al. Antioxidant tert-butylhydroquinone ameliorates arsenic-induced intracellular damages and apoptosis through induction of Nrf2-dependent antioxidant responses as well as stabilization of anti-apoptotic factor Bcl-2 in human keratinocytes. Free Radic. Biol. Med., 2016.
62. [62] Lee, J.S., Surh, Y.J., Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. 224:2 (2005), 171–184.
63. [63] Hayes, J.D., McMahon, M., Chowdhry, S., et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal. 13:11 (2010), 1713–1748.
64. [64] Huang, Y., Li, W., Su, Z.Y., et al. The complexity of the Nrf2 pathway: beyond the antioxidant response. J. Nutr. Biochem. 26:12 (2015), 1401–1413.
65. [65] Moon, E.J., Giaccia, A., Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment. Free Radic. Biol. Med. 79 (2015), 292–299.
66. [66] Singh, A., Bodas, M., Wakabayashi, N., et al. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid. Redox Signal. 13:11 (2010), 1627–1637.
67. [67] Hu, X.F., Yao, J., Gao, S.G., et al. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. Asian Pac. J. Cancer Prev. 14:9 (2013), 5231–5235.
68. [68] Hayes, A.J., Skouras, C., Haugk, B., et al. Keap1-Nrf2 signalling in pancreatic cancer. Int. J. Biochem. Cell Biol. 65 (2015), 288–299.
69. [69] Singh, A., Boldin-Adamsky, S., Thimmulappa, R.K., et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68:19 (2008), 7975–7984.
70. [70] Wang, H., Liu, X., Long, M., et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci. Transl. Med., 8(334), 2016, 334ra51.
71. [71] Espinosa-Diez, C., Miguel, V., Mennerich, D., et al. Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol. 6 (2015), 183–197.
72. [72] Shibata, T., Kokubu, A., Gotoh, M., et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135:4 (2008), 1358–1368 1368.e1-4.
73. [73] Li, Q.K., Singh, A., Biswal, S., et al. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J. Hum. Genet. 56:3 (2011), 230–234.
74. [74] Shibata, T., Ohta, T., Tong, K.I., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA 105:36 (2008), 13568–13573.
75. [75] Guo, Y., Yu, S., Zhang, C., et al. Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic. Biol. Med. 88:Pt B (2015), 337–349.
76. [76] Kansanen, E., Kuosmanen, S.M., Leinonen, H., et al. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 1 (2013), 45–49.
77. [77] Ganan-Gomez, I., Wei, Y., Yang, H., et al. Oncogenic functions of the transcription factor Nrf2. Free Radic. Biol. Med. 65 (2013), 750–764.
78. [78] Uruno, A., Motohashi, H., The Keap1-Nrf2 system as an in vivo sensor for electrophiles. Nitric Oxide: Biol. Chem. 25:2 (2011), 153–160.
79. [79] Yamadori, T., Ishii, Y., Homma, S., et al. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 31:45 (2012), 4768–4777.
80. [80] Jia, Y., Chen, J., Zhu, H., et al. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes. Oncol. Rep. 34:5 (2015), 2296–2304.
81. [81] Niture, S.K., Jaiswal, A.K., Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic. Biol. Med. 57 (2013), 119–131.
82. [82] Ji, X., Wang, H., Zhu, J., et al. Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Int. J. Cancer 135:3 (2014), 574–584.
83. [83] Kim, T.H., Hur, E.G., Kang, S.J., et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res. 71:6 (2011), 2260–2275.
84. [84] Reuter, S., Gupta, S.C., Chaturvedi, M.M., et al. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 49:11 (2010), 1603–1616.
85. [85] Sau, A., Pellizzari Tregno, F., Valentino, F., et al. Glutathione transferases and development of new principles to overcome drug resistance. Arch. Biochem. Biophys. 500:2 (2010), 116–122.
86. [86] Zhou, S., Ye, W., Shao, Q., et al. Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit. Rev. Oncol./Hematol. 88:3 (2013), 706–715.
87. [87] Furfaro, A.L., Piras, S., Passalacqua, M., et al. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib. Biochim. Biophys. Acta 1842:4 (2014), 613–622.
88. [88] Yang, B., Ma, Y.F., Liu, Y., Elevated expression of Nrf-2 and ABCG2 Involved in multi-drug resistance of lung cancer SP cells. Drug Res., 2014.
89. [89] Xu, X., Zhang, Y., Li, W., et al. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Biochem. Pharmacol. 92:2 (2014), 220–234.
90. [90] Arlt, A., Bauer, I., Schafmayer, C., et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 28:45 (2009), 3983–3996.
91. [91] Wang, X.J., Li, Y., Luo, L., et al. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic. Biol. Med. 70 (2014), 68–77.
92. [92] Furfaro, A.L., Piras, S., Domenicotti, C., et al. Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib. PLoS One, 11(3), 2016, e0152465.
93. [93] Zhang, M., Zhang, C., Zhang, L., et al. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer, 15, 2015, 531.
94. [94] Ji, L., Wei, Y., Jiang, T., et al. Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival. Int. J. Clin. Exp. Pathol. 7:3 (2014), 1124–1131.
95. [95] Liew, P.L., Hsu, C.S., Liu, W.M., et al. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Int. J. Clin. Exp. Pathol. 8:5 (2015), 5642–5649.
96. [96] Kawasaki, Y., Okumura, H., Uchikado, Y., et al. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann. Surg. Oncol. 21:7 (2014), 2347–2352.
97. [97] Cescon, D.W., She, D., Sakashita, S., et al. NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma. Clin. Cancer Res. 21:11 (2015), 2499–2505.
98. [98] Qian, Z., Zhou, T., Gurguis, C.I., et al. Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival. Sci. Rep., 5, 2015, 16889.
99. [99] Okano, Y., Nezu, U., Enokida, Y., et al. SNP (-617C>A) in ARE-like loci of the NRF2 gene: a new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women. PLoS One, 8(9), 2013, e73794.
100. [100] Ishikawa, T., Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy. Front. Genet., 5, 2014, 383.
101. [101] Kanninen, K.M., Pomeshchik, Y., Leinonen, H., et al. Applications of the Keap1-Nrf2 system for gene and cell therapy. Free Radic. Biol. Med. 88:Pt B (2015), 350–361.
102. [102] Mendell, J.T., Olson, E.N., MicroRNAs in stress signaling and human disease. Cell 148:6 (2012), 1172–1187.
103. [103] Pecot, C.V., Calin, G.A., Coleman, R.L., et al. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11:1 (2011), 59–67.
104. [104] Leinonen, H.M., Ruotsalainen, A.K., Maatta, A.M., et al. Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. Cancer Res. 72:23 (2012), 6227–6235.
105. [105] Tang, X., Wang, H., Fan, L., et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic. Biol. Med. 50:11 (2011), 1599–1609.
106. [106] Chian, S., Li, Y.Y., Wang, X.J., et al. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac. J. Cancer Prev. 15:6 (2014), 2911–2916.
107. [107] Chian, S., Thapa, R., Chi, Z., et al. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem. Biophys. Res. Commun. 447:4 (2014), 602–608.
108. [108] Horinaka, M., Yoshida, T., Shiraishi, T., et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24:48 (2005), 7180–7189.
109. [109] Xu, H., Yang, T., Liu, X., et al. Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism. Life Sci. 144 (2016), 138–147.
110. [110] Lopez-Lazaro, M., Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 9:1 (2009), 31–59.
111. [111] Shimoi, K., Okada, H., Furugori, M., et al. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett. 438:3 (1998), 220–224.
112. [112] Plaumann, B., Fritsche, M., Rimpler, H., et al. Flavonoids activate wild-type p53. Oncogene 13:8 (1996), 1605–1614.
113. [113] Sak, K., Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacognit. Rev. 8:16 (2014), 122–146.
114. [114] Gao, A.M., Ke, Z.P., Shi, F., et al. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem. Biol. Interact. 206:1 (2013), 100–108.
115. [115] Gao, A.M., Ke, Z.P., Wang, J.N., et al. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 34:8 (2013), 1806–1814.
116. [116] Patel, D., Shukla, S., Gupta, S., Apigenin and cancer chemoprevention: progress, potential and promise (review). Int. J. Oncol. 30:1 (2007), 233–245.
117. [117] Kasala, E.R., Bodduluru, L.N., Madana, R.M., et al. Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives. Toxicol. Lett. 233:2 (2015), 214–225.
118. [118] Weldon, C.B., McKee, A., Collins-Burow, B.M., et al. PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling. Int. J. Oncol. 26:3 (2005), 763–768.
119. [119] Lee, S.J., Yoon, J.H., Song, K.S., Chrysin inhibited stem cell factor (SCF)/c-Kit complex-induced cell proliferation in human myeloid leukemia cells. Biochem. Pharmacol. 74:2 (2007), 215–225.
120. [120] Gupta, S., Afaq, F., Mukhtar, H., Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem. Biophys. Res. Commun. 287:4 (2001), 914–920.
121. [121] Zhang, S., Yang, X., Morris, M.E., Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65:5 (2004), 1208–1216.
122. [122] Lin, C.W., Wu, M.J., Liu, I.Y., et al. Neurotrophic and cytoprotective action of luteolin in PC12 cells through ERK-dependent induction of Nrf2-driven HO-1 expression. J. Agric. Food Chem. 58:7 (2010), 4477–4486.
123. [123] Paredes-Gonzalez, X., Fuentes, F., Jeffery, S., et al. Induction of NRF2-mediated gene expression by dietary phytochemical flavones apigenin and luteolin. Biopharm. Drug Dispos., 2015.
124. [124] Huang, C.S., Lii, C.K., Lin, A.H., et al. Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes. Arch. Toxicol. 87:1 (2013), 167–178.
125. [125] Pandurangan, A.K., Ananda Sadagopan, S.K., Dharmalingam, P., et al. Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling. Toxicol. Mech. Methods 24:1 (2014), 13–20.
126. [126] Tai, M.C., Tsang, S.Y., Chang, L.Y., et al. Therapeutic potential of wogonin: a naturally occurring flavonoid. CNS Drug Rev. 11:2 (2005), 141–150.
127. [127] Zhong, Y., Zhang, F., Sun, Z., et al. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol. Carcinog. 52:10 (2013), 824–834.
128. [128] Qian, C., Wang, Y., Zhong, Y., et al. Wogonin-enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by suppression Nrf2-mediated signaling in HepG2 cells. Free Radic. Res. 48:5 (2014), 607–621.
129. [129] Yao, J., Zhao, L., Zhao, Q., et al. NF-kappaB and Nrf2 signaling pathways contribute to wogonin-mediated inhibition of inflammation-associated colorectal carcinogenesis. Cell Death Dis., 5, 2014, e1283.
130. [130] Lim, J., Lee, S.H., Cho, S., et al. 4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells. Mol. Cells 36:4 (2013), 340–346.
131. [131] Tomazela, D.M., Pupo, M.T., Passador, E.A., et al. Pyrano chalcones and a flavone from Neoraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase-inhibitory activities. Phytochemistry 55:6 (2000), 643–651.
132. [132] Hou, X., Bai, X., Gou, X., et al. 3’,4’,5’,5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway. Mol. Cells 38:5 (2015), 396–401.
133. [133] Cai, H., Sale, S., Schmid, R., et al. Flavones as colorectal cancer chemopreventive agents–phenol-o-methylation enhances efficacy. Cancer Prev. Res. 2:8 (2009), 743–750.
134. [134] Cai, H., Sale, S., Britton, R.G., et al. Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3’,4’,5’,5,7-pentamethoxyflavone and tricin (4’,5,7-trihydroxy-3’,5’-dimethoxyflavone). Cancer Chemother. Pharm. 67:2 (2011), 255–263.
135. [135] Kweon, M.H., Adhami, V.M., Lee, J.S., et al. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem. 281:44 (2006), 33761–33772.
136. [136] Yang, G.Z., Wang, Z.J., Bai, F., et al. Epigallocatechin-3-gallate protects HUVECs from PM2.5-induced oxidative stress injury by activating critical antioxidant pathways. Molecules 20:4 (2015), 6626–6639.
137. [137] Kilic, U., Sahin, K., Tuzcu, M., et al. Enhancement of Cisplatin sensitivity in human cervical cancer: epigallocatechin-3-gallate. Front. Nutr., 1, 2014, 28.
138. [138] Han, S.G., Han, S.S., Toborek, M., et al. EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes. Toxicol. Appl. Pharmacol. 261:2 (2012), 181–188.
139. [139] Lecumberri, E., Dupertuis, Y.M., Miralbell, R., et al. Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin. Nutr. 32:6 (2013), 894–903.
140. [140] Ge, J., Tan, B.X., Chen, Y., et al. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J. Mol. Med. 89:6 (2011), 595–602.
141. [141] Kilani-Jaziri, S., Frachet, V., Bhouri, W., et al. Flavones inhibit the proliferation of human tumor cancer cell lines by inducing apoptosis. Drug Chem. Toxicol. 35:1 (2012), 1–10.
142. [142] Bagli, E., Stefaniotou, M., Morbidelli, L., et al. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3’-kinase activity. Cancer Res. 64:21 (2004), 7936–7946.
143. [143] Ju, W., Wang, X., Shi, H., et al. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol. Pharm. 71:5 (2007), 1381–1388.
144. [144] Seelinger, G., Merfort, I., Wolfle, U., et al. Anti-carcinogenic effects of the flavonoid luteolin. Molecules 13:10 (2008), 2628–2651.
145. [145] Tsai, C.F., Yeh, W.L., Huang, S.M., et al. Wogonin induces reactive oxygen species production and cell apoptosis in human glioma cancer cells. Int. J. Mol. Sci. 13:8 (2012), 9877–9892.
146. [146] Chen, Y., Xue, P., Hou, Y., et al. Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol. Appl. Pharmacol. 273:3 (2013), 435–441.
147. [147] Verma, A.K., Yadav, A., Dewangan, J., et al. Isoniazid prevents Nrf2 translocation by inhibiting ERK1 phosphorylation and induces oxidative stress and apoptosis. Redox Biol. 6 (2015), 80–92.
148. [148] Peng, H., Wang, H., Xue, P., et al. Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. Toxicol. Appl. Pharmacol., 2015.
149. [149] Kawai, Y., Garduno, L., Theodore, M., et al. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem. 286:9 (2011), 7629–7640.
150. [150] J. Pi, M.E. Andersen, P. Xue, et al., Compositions for Modulating NRF2-ARE Activity and their Methods of Use. International Publication Number: WO2015/009879A1, USA, 2015.
151. [151] B. Nelson, J. Pi, M.E. Andersen, NRF2 Inhibitors and Compositions for Treating Mycobacterial Infections. International Publication Number: WO2015/009881A1, USA, 2015.
152. [152] Tarumoto, T., Nagai, T., Ohmine, K., et al. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp. Hematol. 32:4 (2004), 375–381.
153. [153] Wagner, A.E., Boesch-Saadatmandi, C., Breckwoldt, D., et al. Ascorbic acid partly antagonizes resveratrol mediated heme oxygenase-1 but not paraoxonase-1 induction in cultured hepatocytes - role of the redox-regulated transcription factor Nrf2. BMC Complement. Altern. Med., 11, 2011, 1.
154. [154] Kim, S.R., Ha, Y.M., Kim, Y.M., et al. Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals. Biochem. Pharmacol. 95:4 (2015), 279–289.
155. [155] Kurbacher, C.M., Wagner, U., Kolster, B., et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 103:2 (1996), 183–189.
156. [156] Witenberg, B., Kletter, Y., Kalir, H.H., et al. Ascorbic acid inhibits apoptosis induced by X irradiation in HL60 myeloid leukemia cells. Radiat. Res. 152:5 (1999), 468–478.
157. [157] Wilson, M.K., Baguley, B.C., Wall, C., et al. Review of high-dose intravenous vitamin C as an anticancer agent. Asia-Pac. J. Clin. Oncol. 10:1 (2014), 22–37.
158. [158] Wang, H., Liu, K., Geng, M., et al. RXRalpha inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res. 73:10 (2013), 3097–3108.
159. [159] Wang, X.J., Hayes, J.D., Henderson, C.J., et al. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc. Natl. Acad. Sci. USA 104:49 (2007), 19589–19594.
160. [160] Valenzuela, M., Glorieux, C., Stockis, J., et al. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br. J. Cancer 111:5 (2014), 874–882.
161. [161] Schenk, T., Stengel, S., Zelent, A., Unlocking the potential of retinoic acid in anticancer therapy. Br. J. Cancer 111:11 (2014), 2039–2045.
162. [162] Zhou, G.B., Zhang, J., Wang, Z.Y., et al. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 362:1482 (2007), 959–971.
163. [163] Cheung, B.B., Combination therapies improve the anticancer activities of retinoids in neuroblastoma. World J. Clin. Oncol. 6:6 (2015), 212–215.
164. [164] Bollong, M.J., Yun, H., Sherwood, L., et al. A small molecule inhibits deregulated NRF2 transcriptional activity in cancer. ACS Chem. Biol., 2015.
165. [165] Ren, D., Villeneuve, N.F., Jiang, T., et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. USA 108:4 (2011), 1433–1438.
166. [166] Tao, S., Wang, S., Moghaddam, S.J., et al. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 74:24 (2014), 7430–7441.
167. [167] Olayanju, A., Copple, I.M., Bryan, H.K., et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic. Biol. Med. 78 (2015), 202–212.
168. [168] Chen, W., Lu, Y., Chen, G., et al. Molecular evidence of cryptotanshinone for treatment and prevention of human cancer. Anti-Cancer Agents Med. Chem. 13:7 (2013), 979–987.
169. [169] Li, W., Saud, S.M., Young, M.R., et al. Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro. Mol. Cell. Biochem. 406:1–2 (2015), 63–73.
170. [170] Li, S., Wang, H., Hong, L., et al. Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling. Cancer Biol. Ther. 16:1 (2015), 176–184.
171. [171] Wu, C.F., Klauck, S.M., Efferth, T., Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells. Arch. Toxicol., 2015.
172. [172] Xia, C., Bai, X., Hou, X., et al. Cryptotanshinone reverses cisplatin resistance of human lung carcinoma A549 cells through down-regulating Nrf2 Pathway [J], Cellular physiology and biochemistry. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 37:2 (2015), 816–824.
173. [173] Lee, S., Lim, M.J., Kim, M.H., et al. An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic. Biol. Med. 53:4 (2012), 807–816.
174. [174] Do, M.T., Kim, H.G., Khanal, T., et al. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol. Appl. Pharmacol. 271:2 (2013), 229–238.
175. [175] Do, M.T., Kim, H.G., Choi, J.H., et al. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1alpha/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic. Biol. Med. 74 (2014), 21–34.
176. [176] Ashabi, G., Khalaj, L., Khodagholi, F., et al. Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia. Metab. Brain Dis. 30:3 (2015), 747–754.
177. [177] Chae, Y.K., Arya, A., Malecek, M.K., et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget, 2016.
178. [178] Zhang, H.H., Guo, X.L., Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother. Pharm., 2016.
179. [179] Tomic, T., Botton, T., Cerezo, M., et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis., 2, 2011, e199.
180. [180] Shi, W.Y., Xiao, D., Wang, L., et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis., 3, 2012, e275.
181. [181] Jiang, T., Harder, B., Rojo de la Vega, M., et al. p62 links autophagy and Nrf2 signaling. Free Radic. Biol. Med. 88:Pt B (2015), 199–204.
182. [182] Huang, Z., Zhou, L., Chen, Z., et al. Stress management by autophagy: Implications for chemoresistance. Int. J. Cancer 139:1 (2016), 23–32.
183. [183] Limonciel, A., Jennings, P., A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity. Toxins 6:1 (2014), 371–379.
184. [184] Marin-Kuan, M., Nestler, S., Verguet, C., et al. A toxicogenomics approach to identify new plausible epigenetic mechanisms of ochratoxin a carcinogenicity in rat. Toxicol. Sci.: Off. J. Soc. Toxicol. 89:1 (2006), 120–134.
185. [185] Cavin, C., Delatour, T., Marin-Kuan, M., et al. Ochratoxin A-mediated DNA and protein damage: roles of nitrosative and oxidative stresses. Toxicol. Sci.: Off. J. Soc. Toxicol. 110:1 (2009), 84–94.
186. [186] Boesch-Saadatmandi, C., Wagner, A.E., Graeser, A.C., et al. Ochratoxin A impairs Nrf2-dependent gene expression in porcine kidney tubulus cells. J. Anim. Physiol. Anim. Nutr. 93:5 (2009), 547–554.
187. [187] Arlt, A., Sebens, S., Krebs, S., et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32:40 (2013), 4825–4835.
188. [188] Boettler, U., Sommerfeld, K., Volz, N., et al. Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-dependent gene expression. J. Nutr. Biochem. 22:5 (2011), 426–440.
189. [189] Liao, J.C., Lee, K.T., You, B.J., et al. Raf/ERK/Nrf2 signaling pathway and MMP-7 expression involvement in the trigonelline-mediated inhibition of hepatocarcinoma cell migration. Food Nutr. Res., 59, 2015, 29884.
190. [190] Reno, T.A., Kim, J.Y., Raz, D.J., Triptolide inhibits lung cancer cell migration, invasion, and metastasis. Ann. Thorac. Surg. 100:5 (2015), 1817–1824 discussion 1824-5.
191. [191] Li, H., Pan, G.F., Jiang, Z.Z., et al. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERalpha-mediated signaling pathway. Acta Pharmacol. Sin. 36:5 (2015), 606–613.
192. [192] Wang, B.Y., Cao, J., Chen, J.W., et al. Triptolide induces apoptosis of gastric cancer cells via inhibiting the overexpression of MDM2. Med. Oncol., 31(11), 2014, 270.
193. [193] Meng, C., Zhu, H., Song, H., et al. Targets and molecular mechanisms of triptolide in cancer therapy. Chin. J. Cancer Res. 26:5 (2014), 622–626.
194. [194] Ho, J.N., Byun, S.S., Lee, S., et al. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells. J. Urol. 193:3 (2015), 1016–1022.
195. [195] Liu, Y., Chen, F., Wang, S., et al. Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors. Cell Death Dis., 4, 2013, e948.
196. [196] Yu, H., Shi, L., Zhao, S., et al. Triptolide attenuates myocardial ischemia/reperfusion injuries in rats by inducing the activation of Nrf2/HO-1 defense pathway. Cardiovasc. Toxicol., 2015.
197. [197] Zhou, Z.L., Yang, Y.X., Ding, J., et al. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat. Prod. Rep. 29:4 (2012), 457–475.